Top Telehealth Companies (848)

Profitability: Company materials describe sustained annual profitability since 2023 and cash-flow positivity, pairing growth with disciplined financial health. It also reports meeting efficiency benchmarks, noting it exceeded the Rule of 40 in 2025.

Strong Revenue Growth: Disclosures point to multi-year revenue expansion with momentum described as accelerating, indicating robust top-line performance. This growth is presented alongside expanding provider and patient scale.

Strategic Partnerships: The platform is increasingly embedded across external channels through integrations with Healthgrades, Yelp, Google Gemini, and payer portals, broadening distribution and demand capture. These arrangements signal deeper ecosystem reach beyond the core marketplace.

Healthy Cash Flow: Cash generation is strong, with operating and free cash flow increasing year over year and remaining substantial. This indicates the business can fund investments while sustaining stability.

Strong Market Position & Advantage: The platform reports a very large share of U.S. physicians and millions of registered members, alongside broad adoption of workflow tools. This scale supports durable demand from pharmaceutical clients and health systems.

Strong Revenue Growth: Revenue has continued to rise at a double-digit annual pace recently, with steady year-over-year increases across multiple periods. Even as the rate moderates, the top line remains on an upward trajectory.

Strong Revenue Growth: Independent estimates indicate revenue roughly doubled in 2024 to around $471M annualized, pointing to rapid top-line expansion. While privately held and unaudited, the trajectory across 2023–2025 is characterized by accelerated scaling.

Market Expansion: Covered therapy was extended to all 50 states plus Washington, D.C. in 2024, with psychiatry rolled out nationwide by 2025. The network grew from 10,000+ providers in 2024 to 23,000+ by 2026, broadening reach and utilization.

Strategic Partnerships: An Amazon Health program listing and other distribution channels increased visibility and access. A cited OptumCare collaboration saw referrals grow by triple digits year over year, signaling traction in enterprise pathways.

Strong Revenue Growth: Estimates indicate annualized revenue rose sharply in 2024, with acceleration tied to GLP-1/obesity care. Evidence cites roughly $598M annualized revenue in 2024 versus about $360M in 2023.

Market Expansion: Recent launches and channel moves broadened reach, including nationwide availability of the Wegovy pill and a surge of new customers in early 2026. The platform reports helping millions of patients across nearly every U.S. county.

Strategic Partnerships: Direct integrations with major manufacturers (e.g., Novo Nordisk’s NovoCare for Wegovy and additional GLP-1 collaborations) position the company as a distribution/access channel. Novo Nordisk specifically described the company as part of its direct-to-patient expansion.

Strong Revenue Growth: Inc.’s 2026 profile cites exceptional multi-year growth and nine-figure 2025 revenue, signaling unusually fast top-line expansion with third-party validation of the inputs it used. Operating milestones such as surging patient volume and completed appointments align with a company moving from early-stage to substantial scale.

Investor Backing & Capital Strength: Late-stage financings—$70M in 2025 and $100M in 2026—brought total funding to $215M, indicating deep capital access and sustained investor confidence. Reported unicorn-level valuations further underscore the ability to secure significant backing for continued expansion.

Strong Market Position & Advantage: Scale signals including a 10,000+ dietitian network, hundreds of thousands of patients served, nationwide availability, and broad payer reach depict a leading position in dietitian-led virtual nutrition care. Industry recognition (e.g., Inc. 5000 placement and Fierce 15 mentions) adds to perceived competitive advantage.

Strong Revenue Growth: Top-line growth is portrayed as rapid, with claims of seven-figure to near eight-figure ARR and sharp recent acceleration. Company materials also describe an eightfold scale-up alongside broader adoption in hospitals.

Investor Backing & Capital Strength: Capital support appears robust, with backing from Y Combinator and institutional investors such as Oak HC/FT and Norwest, plus reports of a recent Series A and tens of millions raised. This financing base is positioned to fund continued product and market expansion.

Market Expansion: Hospital deployments are expanding, with reports of being live across dozens of facilities and plans to scale significantly. Usage by large numbers of clinical staff and work with top health systems indicate a widening footprint.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list and an Inc. profile noting 27% three-year growth for 2026 indicate sustained top-line expansion.

Market Expansion: Acquisitions in 2023 (ABA Therapy Billing & Insurance Services) and 2025 (Joshin), plus the addition of a Chief Revenue Officer and an SVP of Enterprise Sales, point to expansion across providers, disability support, and enterprise channels.

Innovation-Driven Growth: New AI-enabled capabilities for behavioral-health workflows and analytics recognition suggest product momentum that supports continued scaling.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Strong Revenue Growth: Revenue is reported to have grown 4× in 2023, more than 300% in 2024, and then doubled again in 2025, indicating sustained acceleration. Company communications consistently point to multi‑year, triple‑digit expansion across successive periods.

Investor Backing & Capital Strength: Capital raised includes a $47M Series B in 2024 and a $72M Series C in 2025, bringing total funding to $162M. This level of financing from institutional and strategic investors signals ample resources to support scale.

Strategic Partnerships: Partnerships are described with 7–8 of the top 10 U.S. life insurers and additional organizations such as Prudential, Principal, and Aflac. This enterprise-led distribution has extended access to tens of millions of policyholders and employees.

Strong Revenue Growth: TechCrunch reported that revenue increased six-fold year over year as of May 2025, indicating rapid top-line acceleration.

Market Expansion: The company expanded from 5 states in 2023 to 18 states in 2025 and announced nearly 25 states by February 2026, pointing to broadening geographic coverage.

Investor Backing & Capital Strength: The company closed a $55 million Series B in May 2025, bringing total funding to about $125 million. The round was led by General Catalyst with participation from Andreessen Horowitz, GV, and Accel, underscoring access to capital.

Market Expansion: Geographic reach is described as nationwide through Medicare, with pages indicating coverage in 48 to all 50 states, signaling active expansion. State-by-state therapist listings and nationwide positioning reinforce a broad and growing footprint.

Product Line Growth: Service scope expanded from therapy for older adults to a broader platform that includes behavioral health, advocacy, wellness classes, mind exercises, and AI care agents. This indicates growth beyond the original core offering.

Strong Hiring & Retention: Headcount and hiring activity are depicted as rising quickly, with quarter-over-quarter increases reported by company intelligence trackers and ongoing recruiting across clinical and corporate roles. This workforce build-out supports scaling operations.

Investor Backing & Capital Strength: Capital access is depicted as strong, with a $32M Series A in 2024 followed by an oversubscribed $50M Series B in April 2025 that included $20M in credit. These rounds were led by institutional investors and were linked to observed traction.

Market Expansion: Reach is described at 15,000+ organizations and more than one million U.S. households, with targeting that now includes employers with 5,000–70,000+ eligible employees. Channel additions such as access to 25,000 employer groups via a PEO partner and mid‑market momentum further signal expanding distribution.

Strategic Partnerships: Ecosystem integration is broadening through relationships with TriNet, Workday Wellness, and PrismHR, alongside a Snowflake case study corroborating scale. These partnerships extend distribution and support enterprise penetration.

Strategic Partnerships: Partnership announcements include a national care-management engagement (2025), a Protera Health collaboration for virtual MSK care (2025), and a Brazil-focused alliance with FCamara, signaling continued commercial traction. These collaborations point to active go-to-market momentum with employers, payers, and international partners.

Market Expansion: Operations span the U.S. and Latin America, with the Brazil initiative explicitly aimed at expanding digital healthcare capabilities. Member reach is described as 26 million in recent materials and 28 million in 2024, reflecting a sizable footprint across geographies.

Product Line Growth: New AI-powered offerings launched in 2024–2026 include generative-AI applications with Google Cloud, an AI Wellness Agent, an AI Behavioral Health Agent, and the Pager Health Navigator platform. These rollouts indicate sustained broadening of the solution set.

Investor Backing & Capital Strength: Major funding and valuation milestones are highlighted by a $92 million Series C led by Stripes, elevating valuation to $1.7 billion and bringing total capital raised to roughly $171–$187 million. Backing from firms like Andreessen Horowitz and First Round Capital signals deep capital support.

Market Expansion: National scale has accelerated through commercial and Medicaid health plan partnerships, expanding coverage to more than 25 million lives across women’s and children’s health. The platform broadened beyond maternity into reproductive care, pediatrics, hormonal health, and midlife programs.

Strategic Partnerships: Collaborations with major payers such as Aetna and UnitedHealthcare enable value-based virtual care at scale and integration across plans and employers. Acquisitions like The Doula Network also extend capabilities across virtual and in-person care.

Strong Market Position & Advantage: Within care enablement and digital front door, the company is described as a category leader with unusually comprehensive coverage across triage, navigation, scheduling, virtual visits, and a 50‑state clinical network. Third‑party lists (CB Insights, DHNY, AVIA) and scale signals (relationships with 75+ health systems and 30,000 employers) suggest rising standing among peers.

Strong Revenue Growth: Company materials cite triple‑digit annual sales growth alongside ongoing product launches and new deployments through 2025–2026. Reported reach of roughly 100M covered lives and expanding enterprise relationships indicate accelerating topline momentum.

Investor Backing & Capital Strength: A $60M Series A in 2024 aligns with an aggressive build‑and‑buy strategy that includes multiple acquisitions over a short period. This funding posture supports continued platform development and distribution expansion.